Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02752282
Other study ID # 49648
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 2016
Est. completion date December 2019

Study information

Verified date April 2019
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a counseling intervention for new LNG-IUS users. The study explores the use of video technology to deliver anticipatory counseling on LNG-IUS side-effects, adjustment periods and bleeding changes to women newly using the LNG-IUS for contraceptive purposes. The primary aim is to understand if anticipatory counseling delivered via video can increase LNG-IUS satisfaction and continuation of the device in the first 6 months of use.


Description:

Enhanced anticipatory counseling detailing side effects when initiating progestin-only injectable contraception improved its continued use among women.While continuation rates at one year among levonorgestrel intrauterine system (LNG-IUS) users are considerably higher than those for progestin-only injectable users in the United States (80% versus 56%), enhanced anticipatory counseling could have an impact on the 20% of LNG IUS users who choose to discontinue the method within one year of use. For this reason, the investigators propose a study that would develop and pilot-test an anticipatory counseling intervention detailing unscheduled bleeding and other side effects such as pelvic pain or cramping among new LNG IUS users and compare this with a "control," using video technology. The investigators have chosen video technology for the counseling intervention to ensure that all participants receive the exact same information about LNG side effects, which would be not possible using a face-to-face clinician-participant counseling model.

The investigators propose three phases for this study. In Phase 1, a systematic literature search evaluating effective components in videos used for contraceptive counseling and the development of two separate video scripts will lead to: (1) an intervention, detailing expected side effects and safety of the LNG IUS, and (2) a similar-looking "control," detailing only recommended screening guidelines for women, as well as information about LNG IUS safety. This phase of the study uses focus groups prior to the development of the video interventions, initially with family planning experts for content accuracy and cultural sensitivity, and secondarily with new LNG IUS users for acceptability. Findings from this phase will be used to fine-tune the scripts prior to the development of the videos.

In Phase 2 of the study, the investigators will pilot a trial in the clinical setting to evaluate the anticipatory counseling video intervention and its impact on LNG-IUS knowledge, continuation, health care utilization, and satisfaction. After receiving comprehensive contraceptive counseling from their clinicians, women who choose to have the LNG IUS inserted will be given a brochure that asks them to participate in an online study. After signing-on to an innovative website, participants will be randomized to either an intervention or control video and complete short questionnaires related to demographics, baseline menstruation, satisfaction, and LNG IUS knowledge before and after viewing their assigned video. Women will be followed for six months. They will be asked to complete a short online survey at three and six months regarding LNG IUS continuation, health care utilization, and satisfaction. Findings from this study will serve to design a future, appropriately powered randomized controlled trial assessing LNG IUS continuation, utilization, and satisfaction rates at 12 months.

In Phase 3, we will use the findings from Phase 2 to develop a similar protocol and recruit up to 178 women at three sites across the US to test the same primary aims of the video: LNG-IUS continuation, utilization, and satisfaction over a 12 month period. In phase 3, subjects will be randomized to watch either the control or intervention video.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 178
Est. completion date December 2019
Est. primary completion date October 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Women aged 18 and over who are deemed appropriate candidates be their healthcare providers and choose to use LNG-IUS, either Mirena or Skyla.

2. Within five days of FIRST using either Mirena or Skyla

3. Willing to answer online questions before and after watching the assigned video (intervention or control)

4. Willing to complete short online questionnaire at three and six months

5. Has working email and/or phone number

6. Able to understand verbal and written English

7. Appropriate LNG-IUS candidates whoa re being treated for other pre-existing medical disorders while using the LNG IUS may continue to take their medications as directed by their healthcare provider.

Exclusion Criteria:

1. Women aged less than 18 years old

2. Initiated LNG-IUS method more than five days from enrollment date.

3. Within six weeks postpartum

4. Breastfeeding

5. Using LNG-IUS for treatment other than contraception

6. Do not have access to the Web

7. Have neither working email or phone number

8. Does not understand written or verbal English

9. Inappropriate candidates for LNG IUS as deemed by healthcare provider

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Anticipatory Counseling
Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
Cancer Screening Guidelines
Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines

Locations

Country Name City State
United States Stroger Hospital of Cook County Chicago Illinois
United States University of California Los Angeles Medical Center Los Angeles California
United States University of Washington Medical Centers Seattle Washington

Sponsors (4)

Lead Sponsor Collaborator
University of Washington Bayer, John H. Stroger Hospital, University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in LNG-IUS knowledge, satisfaction and continuation from baseline Using standardize questionnaires we will assess any significant differences in LNG-IUS knowledge, satisfaction or continuation after 6 months between control arm and intervention arm subjects. 6 months
Secondary Percent of subjects in Phase II who complete all 3 surveys on-time over 6 months compared by recruitment method and site Assess what percent of study participants were successfully recruited via a brochure or email contact at Seattle and Chicago. 6 months
Secondary Number of subjects reporting LNG-IUS discontinuation during the study time frame (6 months) by reason for LNG-IUS removal Track number of subjects who have their LNG-IUS removed during the study period by reason, including: bleeding, cramping, acne, weight gain, depression or other reasons. 6 months
Secondary LNG-IUS user self-reported satisfaction with video counseling A survey using modified likert scales and free text boxes, will ask participants how helpful the video was, how many times they watched the video, and any feedback they had about video elements to improve. 6 months
Secondary LNG-IUS user self-reported LNG-IUS healthcare utilization during study period Compare LNG-IUS user self-reported healthcare utilization at baseline (before the LNg-IUS was placed) with 3 and 6 months after LNG-IUS use. This include number of phone calls and office visits and the user reported helpfulness of these interactions with their healthcare providers. baseline, 3 months, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT00921778 - Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern N/A
Completed NCT02472184 - Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy N/A
Recruiting NCT04612881 - Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.
Completed NCT00339651 - Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Withdrawn NCT04933240 - Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial Phase 4
Completed NCT05668806 - RWE Study in the Treatment of Cervical Lesions of Various Etiology
Terminated NCT04277962 - Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial N/A
Completed NCT02385747 - Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding N/A
Completed NCT03856307 - Reliability of Simple Sonographic Findings Acquired With Hand-held Apparatuses to Inform Obstetric Diagnosis
Completed NCT01868308 - Screening To Obviate Preterm Birth N/A
Completed NCT05840471 - Tranexamic Acid as an Intervention in Abruptio Placenta N/A
Not yet recruiting NCT05645848 - The Rate and Predictors of Vaginal Bleeding Among Women With Placenta Previa
Completed NCT05661708 - Use of Chitosan Powder in Loop Electrosurgical Excision Procedure Phase 4
Completed NCT03074903 - Does Skyla Insertion Timing Impact Bleeding? N/A